Publication Name	World Journal of Hepatology
Manuscript ID	17417
Country	Japan

Received	2015-03-06 08:48
Peer-Review Started	2015-03-06 15:35
To Make the First Decision	2015-04-27 15:48
Return for Revision	2015-04-28 17:48
Revised	2015-05-11 06:10
Second Decision	2015-06-01 08:53
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-06-11 16:03
Articles in Press	2015-06-11 16:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-26 13:56
Publish the Manuscript Online	2015-06-29 17:40

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Efficacy of tolvaptan in patients with refractory ascites in a clinical setting
Manuscript Source	Unsolicited Manuscript
All Author List	Takamasa Ohki, Koki Sato, Tomoharu Yamada, Mari Yamagami, Daisaku Ito, Koki Kawanishi, Kentaro Kojima, Michiharu Seki, Nobuo Toda and Kazumi Tagawa
Funding Agency and Grant Number
Corresponding Author	Takamasa Ohki, MD, PhD, Department of Gastroenterology, Mitsui Memorial Hospital, 1 Kandaizumicho, Chiyoda-ku, Tokyo 101-8643, Japan. anb72547@nifty.com
Key Words	Refractory ascites; Tolvaptan; Paracentesis; Decompensated cirrhosis
Core Tip	Tolvaptan (TLV) was effective in 38 (63.3%) refractory ascites patients. The best cut-off values for urine output and reduced urine osmolality as measures of refractory ascites improvement were > 1800 mL within the first 24 h and > 30%, respectively. The cumulative incidence rate was significantly higher in the control group with a median incidence time of 30 d in the TLV group and 20 d in the control group. Administration of TLV results in better control of refractory ascites and reduced the incidence of additional invasive procedures or hospitalization compared with conventional ascites treatments.
Publish Date	2015-06-29 17:40
Citation	Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015; 7(12): 1685-1693
URL	http://www.wjgnet.com/1948-5182/full/v7/i12/1685.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i12.1685

Full Article (PDF)	WJH-7-1685.pdf
Full Article (Word)	WJH-7-1685.doc
Manuscript File	17417-Review.doc
Answering Reviewers	17417-Answering reviewers.pdf
Audio Core Tip	17417-Audio core tip.mp3
Biostatistics Review Certificate	17417-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	17417-Conflict-of-interest statement.pdf
Copyright License Agreement	17417-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	Informed_Consent_Statement_20150305183214.docx
Institutional Review Board Approval Form or Document	17417-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	17417-Language certificate.pdf
Peer-review Report	17417-Peer-review(s).pdf
Scientific Misconduct Check	17417-Scientific misconduct check.pdf
Scientific Editor Work List	17417-Scientific editor work list.pdf